Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...
Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...
ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role ...
Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...
Two papers present strong evidence that the codon-anticodon interaction is poised on a tipping point so that, given a nudge, the tRNA can insert the wrong amino acid into the growing polypeptide chain ...
The Cambridge programme opened with keynote contributions from George Freeman MP, Prof Deborah Prentice, vice-chancellor of ...
Recently published Huntington's Disease Market Insights report includes a comprehensive understanding of current treatment ...
JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the development and ...
Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.
Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development.
Faire mieux avec moins ? C'est le principe qu'a mis en place Cambridge pour mettre au point une nouvelle forme de vie parfaite.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results